New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
08:21 EDTINFIInfinity Pharmaceuticals upgraded to Outperform at William Blair
William Blair upgraded Infinity Pharmaceuticals to Outperform from Market Perform following the company's Q2 results but lowered its price target for shares to $14.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:31 EDTINFIInfinity Pharmaceuticals reports results from Phase 1 study of duvelisib
Infinity Pharmaceuticals reported updated data from a Phase 1 monotherapy study of duvelisib, an inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma, a fatal type of blood cancer. In the study, duvelisib demonstrated an overall response rate of 72%, including a 33% complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies. In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma.
December 8, 2014
10:47 EDTINFIInfinity reports updated Phase 1 data from duvelisib study, says well tolerated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use